Author

J. G. Berdeja

Observed names: J Berdeja, J. Berdeja, JG Berdeja

Institution: Tennessee Oncology

Observed institutions: Loma Linda University, Louisiana State University in Shreveport, Henry Ford Hospital, Sarah Cannon, Tennessee Oncology, Wake Forest University Health Sciences

OpenAlex ID: A5082897883

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

2015 · J. G. Berdeja, L. L. Hart, et al. · Haematologica · 88

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

2018 · J. Berdeja, F. Palandri, et al. · Leukemia Research · 53

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

2011 · J. G. Berdeja, S. Ailawadhi, et al. · Journal of Clinical Oncology · 35

Updated Results From the Cartitude-1 Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/refractory Multiple Myeloma

2021 · SZ Usmani, JG Berdeja, et al. · Hematology Transfusion and Cell Therapy · 22

P19: Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, Bb2121), a Bcma-directed Car T Cell Therapy in Patients With Relapsed and Refractory Multiple Myeloma: Subanalysis of the Karmma Trial

2022 · P Rodríguez-Otero, N Shah, et al. · HemaSphere · 6

A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

2005 · M. Lilly, P. Kuriakose, et al. · Journal of Clinical Oncology · 5

P961: Ciltacabtagene Autoleucel, a Bcma-directed Car-t Cell Therapy, in Patients With Relapsed/refractory Multiple Myeloma: 2-year Post Lpi Results From the Phase 1b/2 Cartitude-1 Study

2022 · Y. Lin, T. Martin, et al. · HemaSphere · 3

S182: Talquetamab, a G Protein-coupled Receptor Family C Group 5 Member D X Cd3 Bispecific Antibody, in Relapsed/refractory Multiple Myeloma: Updated Efficacy and Safety Results From Monumental-1

2022 · M. C. Minnema, A. Krishnan, et al. · HemaSphere · 2

Talquetamab, a G Protein-coupled Receptor Family C Group 5 Member D (gprc5d) Cd3 Bispecific Antibody for Relapsed/refractory Multiple Myeloma (rrmm): Updated Phase 1 Study Results

2021 · JG Berdeja, AY Krishnan, et al. · Hematology Transfusion and Cell Therapy · 2

Remissão E Sobrevida De Longo Prazo (≥5 Anos) Após Tratamento Com Ciltacabtagene Autoleucel (cilta-cel) Em Pacientes Do Cartitude-1 Com Mieloma Múltiplo Recidivado/refratário (rrmm)

2025 · T Queiroz, P Voorhees, et al. · Hematology Transfusion and Cell Therapy

P971: Adjusted Comparison of Patient Reported Outcomes From Cartitude-1 and Locommotion Comparing Ciltacabtagene Autoleucel Versus Real World Clinical Practice in Triple-class Exposed Multiple Myeloma

2022 · K. Weisel, M.-V. Mateos, et al. · HemaSphere

P13: Can Patient-reported Ocular Symptoms Guide Dose Modifications in Patients With Relapsed/refractory Multiple Myeloma Receiving Belantamab Mafodotin?

2022 · R Popat, A Badros, et al. · HemaSphere

B05: Results From a Meta-analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice of Treatment in Patients With Relapsed or Refractory Multiple Myeloma

2022 · F Gay, JG Berdeja, et al. · HemaSphere

Works count: 13

Citation count: 216

H-index: 5

I10-index: 4